Robert J. More
Robert J. More's purchase track record
Robert J. More has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/17/2021 | TYRA | $2.50M | -37.2% | -36.1% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop. Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.
Transaction History
| VIR | ▼ Sell | Other | 8,000 | $0 | 8/11/2026 | View on chart |
| VIR | ▼ Sell | Other | 8,000 | $0 | 8/11/2026 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/27/2026 | View on chart |
| TYRA | ▼ Sell | Open Market | 10,000 | $250K | 12/19/2025 | View on chart |
| TYRA | ▼ Sell | Open Market | 246,871 | $5.0M | 11/21/2025 | View on chart |
| VIR | ▼ Sell | Other | 14,027 | $0 | 6/9/2025 | View on chart |
| VIR | ▼ Sell | Other | 14,027 | $0 | 6/9/2025 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/30/2025 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 5/30/2024 | View on chart |
| VIR | ▼ Sell | Other | 6,405 | $0 | 10/19/2023 | View on chart |
| VIR | ▼ Sell | Other | 6,405 | $0 | 10/19/2023 | View on chart |
| VIR | ▲ Buy | Grant | 6,027 | $0 | 5/22/2023 | View on chart |
| VIR | ▼ Sell | Other | 3,374 | $0 | 6/9/2022 | View on chart |
| VIR | ▼ Sell | Other | 3,374 | $0 | 6/9/2022 | View on chart |
| VIR | ▲ Buy | Grant | 6,405 | $0 | 5/23/2022 | View on chart |
| TYRA | ▲ Buy | Open Market | 156,250 | $2.5M | 9/17/2021 | View on chart |
| TYRA | ▼ Sell | Other | 3,811,117 | — | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates
Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.